Oxygenta Pharmaceutical Ltd vs Divis Laboratories Ltd

A side-by-side comparison of Oxygenta Pharmaceutical Ltd (524636) and Divis Laboratories Ltd (DIVISLAB) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Divis Laboratories Ltd leads 524636 vs DIVISLAB on 8 of 14 metrics (2 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

0.00
P/E ratio
83.28
-4.18
P/B ratio
10.62
0.00%
Dividend yield
0.41%
₹-2.62
EPS
₹96.73

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

38.69%
Return on equity
16.50%
-25.00%
Return on capital
22.00%
-9.00%
EBITDA margin
33.00%
-9.17%
Net margin
24.32%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

53.89%
Revenue CAGR (3Y)
10.78%
Profit CAGR (3Y)
12.10%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹185 Cr
Market cap
₹2.14L Cr
₹109 Cr
Revenue
₹10,560 Cr
₹-10 Cr
Net profit
₹2,568 Cr
0.00
Debt / equity
0.00
Oxygenta Pharmaceutical Ltd
  • + ["Company's median sales growth is 22.1% of last 10 years"]
  • ["Company has low interest coverage ratio."]
Divis Laboratories Ltd
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 12.8 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
Oxygenta Pharmaceutical Ltd full analysis Divis Laboratories Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

524636 vs Divis Laboratories Ltd: Share Price, Valuation & Which to Buy | DocStoX